Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Pariente
Edouard Louis

Showing results (271-280 of 364) with videos related to

Pageof 37
Sort By:
Mucosal Immunology|October 20, 2019
Epithelial RABGEF1 deficiency promotes intestinal inflammation by dysregulating intrinsic MYD88-dependent innate signalingSophie El Abbas, Coraline Radermecker, Qiang Bai, et al.
Journal of Proteomics|May 19, 2024
Serum proteome signatures associated with ileal and colonic ulcers in Crohn's diseaseNicolas Pierre, Vân Anh Huynh-Thu, Dominique Baiwir, et al.
Inflammatory Bowel Diseases|January 9, 2007
Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitisFady Daniel, Marie-Anne Loriot, Philippe Seksik, et al.
The Patient|January 31, 2020
A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient PerspectiveEdouard Louis, Juan M Ramos-Goñi, Jesus Cuervo, et al.
Journal of Crohn'S & Colitis|July 24, 2025
Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: 2-Year Results from the U-ENDURE Long-Term Extension StudyEdward V Loftus, Geert D'Haens, Edouard Louis, et al.
Journal of Crohn'S & Colitis|December 3, 2010
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspectsMatthieu Allez, Konstantinos Karmiris, Edouard Louis, et al.
Clinical Proteomics|March 28, 2017
OLFM4, KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early colorectal cancer stagesFlorence Quesada-Calvo, Charlotte Massot, Virginie Bertrand, et al.
Inflammatory Bowel Diseases|August 24, 2021
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II StudyGeert R D'Haens, Walter Reinisch, Scott D Lee, et al.
Revista Espanola De Enfermedades Digestivas|May 27, 2020
Diet as an environmental trigger in inflammatory bowel disease: a retrospective comparative study in two European cohortsCarmen Monica Preda, Teodora Manuc, Andreea Chifulescu, et al.
Gastroenterology|September 28, 2011
Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stoppedEdouard Louis, Jean-Yves Mary, Gwenola Vernier-Massouille, et al.
Pageof 37

Showing results (271-280 of 364) with videos related to

Sort By:
Pageof 37
Mucosal Immunology|October 20, 2019
Epithelial RABGEF1 deficiency promotes intestinal inflammation by dysregulating intrinsic MYD88-dependent innate signalingSophie El Abbas, Coraline Radermecker, Qiang Bai, et al.
Journal of Proteomics|May 19, 2024
Serum proteome signatures associated with ileal and colonic ulcers in Crohn's diseaseNicolas Pierre, Vân Anh Huynh-Thu, Dominique Baiwir, et al.
Inflammatory Bowel Diseases|January 9, 2007
Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitisFady Daniel, Marie-Anne Loriot, Philippe Seksik, et al.
The Patient|January 31, 2020
A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient PerspectiveEdouard Louis, Juan M Ramos-Goñi, Jesus Cuervo, et al.
Journal of Crohn'S & Colitis|July 24, 2025
Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: 2-Year Results from the U-ENDURE Long-Term Extension StudyEdward V Loftus, Geert D'Haens, Edouard Louis, et al.
Journal of Crohn'S & Colitis|December 3, 2010
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspectsMatthieu Allez, Konstantinos Karmiris, Edouard Louis, et al.
Clinical Proteomics|March 28, 2017
OLFM4, KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early colorectal cancer stagesFlorence Quesada-Calvo, Charlotte Massot, Virginie Bertrand, et al.
Inflammatory Bowel Diseases|August 24, 2021
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II StudyGeert R D'Haens, Walter Reinisch, Scott D Lee, et al.
Revista Espanola De Enfermedades Digestivas|May 27, 2020
Diet as an environmental trigger in inflammatory bowel disease: a retrospective comparative study in two European cohortsCarmen Monica Preda, Teodora Manuc, Andreea Chifulescu, et al.
Gastroenterology|September 28, 2011
Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stoppedEdouard Louis, Jean-Yves Mary, Gwenola Vernier-Massouille, et al.
Pageof 37